Difference between revisions of "Talazoparib (Talzenna)"
Jump to navigation
Jump to search
(Created page with "==Mechanism of action== PARP inhibitor ==Diseases for which it is used== *BRCA-mutated breast cancer ==History of changes in FDA indication==...") |
m |
||
| Line 9: | Line 9: | ||
==Also known as== | ==Also known as== | ||
| − | *''Code name:''' BMN-673 | + | *'''Code name:''' BMN-673 |
*'''Brand name:''' Talzenna | *'''Brand name:''' Talzenna | ||
Revision as of 02:09, 17 October 2018
Mechanism of action
PARP inhibitor
Diseases for which it is used
History of changes in FDA indication
- 10/16/2018: Initial approval " for patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm), HER2‑negative locally advanced or metastatic breast cancer."
Also known as
- Code name: BMN-673
- Brand name: Talzenna